Parkinson's Disease Drugs Market Global Industry Share, Future Growth

 The global Parkinson's disease drugs market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson's disease. According to a report published by Fortune Business Insights, titled “Parkinson’s Disease Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 4,500.0 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,383.2 Mn by 2026, thereby exhibiting a CAGR of 8.1%.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655

Increasing usage approvals are contributing to the growth of the global Parkinson's disease drugs market. The Food and Drug Administration recently cleared two new drugs for the treatment of Parkinson’s disease. The drug approvals for Rytary and Duopa will emerge as breakthroughs in the healthcare industry.

The report offers an elaborative analysis of numerous factors affecting the global Parkinson’s Disease Drugs Market. These include opportunities, growth drivers, threats, key developments, and restraints. In addition to this, the report can further help in analyzing, segmenting, and defining the market based on different segments. It strategically analyzes several strategies such as product innovations, mergers, alliances, joint ventures, and acquisitions adopted by players in the industry.

Leading Players operating in the Parkinson’s Disease Drugs Market are:

  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis
  • Orion Pharma Ltd
  • UCB S.A
  • Teva Pharmaceutical Industries Ltd.
  • Vertical Pharmaceuticals, LLC
  • ACADIA Pharmaceuticals Inc.
  • Impax Laboratories, Inc.
  • Lundbeck A/S.

AbbVie gets FDA Nod for Orphan Drug ‘Duopa’

The report includes an in-depth analysis of various drug approvals and their effect on the global market. In addition to the clearance for Rytary, the FDA approved another drug in the same year which was also associated with the treatment of Parkinson’s disease. ‘AbbVie’, a pharmaceutical company, announced that it had received approval for the commercialization of its ‘Duopa’. The duopa can be used for treating fluctuations in patients diagnosed with advanced Parkinson's disease. The Duopa was classified as an orphan drug as it is used to treat a rare disease that is affecting fewer than 200,000 people in the United States. Fortune Business Insights has predicted that the aforementioned drug approvals may have a direct impact on the vendor scale. Competitors are likely to be encouraged by the approvals for Parkinson’s disease drugs. This, in turn, is likely to favor growth of the global market in the coming years.

Comments

Post a Comment

Popular posts from this blog

U.S. Acne Treatment Market 2023 Growth, Trends, Demand and Business Opportunities -2029

The recently released Fortune Business Insights™ research on the  U.S. Acne Treatment Market   survey report provides facts and statistics regarding market structure and size. Global U.S. Acne Treatment Market Industry, 2023-2028 Research report presents an in-depth analysis of the U.S. Acne Treatment Market size, growth, share, segments, manufacturers, and forecast, competition landscape and growth opportunity. The U.S. acne treatment market size was valued at USD 4.27 billion in 2021. The market is projected to grow from USD 4.50 billion in 2022 to USD 6.12 billion by 2029, exhibiting a CAGR of 4.5% during the forecast period. Get a Free Sample PDF Brochure  –  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/106565 Acne is a skin condition that occurs due to the plugging of hair follicles with sebum, oil, dirt, and dead skin cells. According to the published articles, acne is the most common disease in the U.S., it affects an estimated 80% of the total population a
Read more

Remote Patient Monitoring Devices Market Recent Development, Share, Size, Segments and Revenue Forecast

  The global   Remote Patient Monitoring Devices   Market Share provides market insights to help companies make better business decisions and advance growth plans, based on market forecasts and trends. The dynamic structure of the market, product offerings of key players, their challenges, technical innovation, hurdles and barriers, sales and communication information, sales by country, risk, outlook, landscape competitive, growth strategy, and so on are all marketing variables covered in the study. Explore in depth the current and emerging state of the industry. The study looks at a number of factors, including the degrees of advancement and the various strategies used by the current major players in the market. Request a Free Sample PDF:  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/106328 The global remote patient monitoring devices market size was USD 25.32 billion in 2020. The market is expected to grow from USD 30.05 billion in 2021 to USD 101.02 billion in
Read more

 Dental Prosthetics Market Size, Segmentation, Growth Factor,  Demands, Analysis, Regional Forecast to 2028

 The global Dental Prosthetics Market Share provides market insights to help companies make better business decisions and advance growth plans, based on market forecasts and trends. The dynamic structure of the market, product offerings of key players, their challenges, technical innovation, hurdles and barriers, sales and communication information, sales by country, risk, outlook, landscape competitive, growth strategy, and so on are all marketing variables covered in the study. Explore in depth the current and emerging state of the industry. The study looks at a number of factors, including the degrees of advancement and the various strategies used by the current major players in the market. Request a Free Sample PDF:  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102677 The global dental prosthetics market size was USD 6.09 billion in 2018 and is projected to reach USD 9.71 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period. Key market pla
Read more